Adrian T Fung1, Suzanne Yzer, Naomi Goldberg, Hao Wang, Michael Nissen, Alfonso Giovannini, Joanna E Merriam, Elena N Bukanova, Carolyn Cai, Lawrence A Yannuzzi, Stephen H Tsang, Rando Allikmets. 1. *Vitreous-Retina-Macula Consultants of New York and the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Institute, New York, New York; †Department of Ophthalmology, Columbia University, New York, New York; ‡Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York; §Department of Pathology and Cell Biology, Columbia University, New York, New York; ¶Albany Medical Center, Albany, New York; **Department of Ophthalmology, Weill Cornell Medical College, New York, New York; ††Ophthalmology Section, Department of Neuroscience, Polytechnic University of Marche, Ancona, Italy; ‡‡Australian School of Advanced Medicine, Macquarie University Hospital, Sydney, Australia; and §§Save Sight Institute, University of Sydney, Sydney, Australia.
Abstract
PURPOSE: To report the ocular phenotype in patients with autosomal recessive bestrophinopathy and carriers, and to describe novel BEST1 mutations. METHODS: Patients with clinically suspected and subsequently genetically proven autosomal recessive bestrophinopathy underwent full ophthalmic examination and investigation with fundus autofluorescence imaging, spectral domain optical coherence tomography, electroretinography, and electrooculography. Mutation analysis of the BEST1 gene was performed through direct Sanger sequencing. RESULTS: Five affected patients from four families were identified. Mean age was 16 years (range, 6-42 years). All affected patients presented with reduced visual acuity and bilateral, hyperautofluorescent subretinal yellowish deposits within the posterior pole. Spectral domain optical coherence tomography demonstrated submacular fluid and subretinal vitelliform material in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of the vitelliform material was seen to change over a follow-up period of 3 years despite relatively stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations including normal fundus autofluorescence. Three novel mutations were detected. CONCLUSION: Three novel BEST1 mutations are described, suggesting that many deleterious variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform macular dystrophy-associated dominant mutations.
PURPOSE: To report the ocular phenotype in patients with autosomal recessive bestrophinopathy and carriers, and to describe novel BEST1 mutations. METHODS:Patients with clinically suspected and subsequently genetically proven autosomal recessive bestrophinopathy underwent full ophthalmic examination and investigation with fundus autofluorescence imaging, spectral domain optical coherence tomography, electroretinography, and electrooculography. Mutation analysis of the BEST1 gene was performed through direct Sanger sequencing. RESULTS: Five affected patients from four families were identified. Mean age was 16 years (range, 6-42 years). All affected patients presented with reduced visual acuity and bilateral, hyperautofluorescent subretinal yellowish deposits within the posterior pole. Spectral domain optical coherence tomography demonstrated submacular fluid and subretinal vitelliform material in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of the vitelliform material was seen to change over a follow-up period of 3 years despite relatively stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations including normal fundus autofluorescence. Three novel mutations were detected. CONCLUSION: Three novel BEST1 mutations are described, suggesting that many deleterious variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform macular dystrophy-associated dominant mutations.
Authors: Arundhati Dev Borman; Alice E Davidson; James O'Sullivan; Dorothy A Thompson; Anthony G Robson; Elfride De Baere; Graeme C M Black; Andrew R Webster; Graham E Holder; Bart P Leroy; Forbes D C Manson; Anthony T Moore Journal: Arch Ophthalmol Date: 2011-08
Authors: L Zhao; S Grob; R Corey; M Krupa; J Luo; H Du; C Lee; G Hughes; J Lee; J Quach; J Zhu; P X Shaw; I Kozak; K Zhang Journal: Eye (Lond) Date: 2012-03-16 Impact factor: 3.775
Authors: Adiv A Johnson; Yong-Suk Lee; Andrew J Chadburn; Paolo Tammaro; Forbes D Manson; Lihua Y Marmorstein; Alan D Marmorstein Journal: Exp Eye Res Date: 2014-02-19 Impact factor: 3.467
Authors: Alice E Davidson; Panagiotis I Sergouniotis; Rosemary Burgess-Mullan; Nichola Hart-Holden; Sancy Low; Paul J Foster; Forbes D C Manson; Graeme C M Black; Andrew R Webster Journal: Mol Vis Date: 2010-12-31 Impact factor: 2.367
Authors: Hema L Ramkumar; Harini V Gudiseva; Kameron T Kishaba; John J Suk; Rohan Verma; Keerti Tadimeti; John A Thorson; Radha Ayyagari Journal: Genet Test Mol Biomarkers Date: 2016-12-22
Authors: Karina E Guziewicz; Divya Sinha; Néstor M Gómez; Kathryn Zorych; Emily V Dutrow; Anuradha Dhingra; Robert F Mullins; Edwin M Stone; David M Gamm; Kathleen Boesze-Battaglia; Gustavo D Aguirre Journal: Prog Retin Eye Res Date: 2017-01-19 Impact factor: 21.198
Authors: Rashi Arora; Kamron Khan; Melissa L Kasilian; Rupert W Strauss; Graham E Holder; Anthony G Robson; Dorothy A Thompson; Anthony T Moore; Michel Michaelides Journal: Am J Ophthalmol Date: 2016-06-07 Impact factor: 5.258
Authors: Qingqing Zhao; Yang Kong; Alec Kittredge; Yao Li; Yin Shen; Yu Zhang; Stephen H Tsang; Tingting Yang Journal: Elife Date: 2021-06-01 Impact factor: 8.140